Upper left picture is a standard trichome. One straight stem with one bulbous head, containing the Entourage Effect (the medicinal properties).

While the anchor picture is The Haivyan Helix Trichome, never before seen, spiraling trichome stem developing multiple bulbous heads, all containing the Entourage Effects (the medicinal properties).

Our Current Early Valuation: $35 Million

Haivya is currently valued at $35 Million based on its early pioneering intellectual property, early experimental results, and the growing demand for non-synthetic terpene rich cannabis therapeutics.

This valuation reflects:

• Three filed patents pending (led by a dream IP legal team) covering our frequency based enhancement methods, not only including its use in cannabis, but all medicinal plants and agricultural crops that could benefit (i.e. terpene rich Lavender, Basil and Hops). Our methods trigger rare genetic expressions such as whorled phyllotaxy (3 or more leaves per node, cannabis usually grows 2) and enhance cannabinoid/terpene expression.

• The emergence of several novel and repeating plant traits in early trials including: novel phenotypes Edenya and Echo, the Haivyan Star (a five leaf phyllotaxy), the Haivyan Cascade (whorling at lateral branches), fasciation and apical proliferation, and NOW the Haivyan Helix trichome suggesting proprietary morphogenic potential and enhanced cannabinoid/terpene expression.

• A unique convergence of botanical science and vibrational therapy that positions Haivya at the forefront of wellness driven biotech with a massive pharmaceutical platform potential.

Future Potential: $200-500 Million+

Pending lab verification of Haivya’s impact on cannabinoid and terpene expression, we anticipate a rapid leap in valuation, potentially reaching $200 to $500 million or higher.

Upon Confirmation, Haivya stands to:

• Create entirely new cultivars and chemical profiles not seen in traditional cannabis.

• License its methods to pharmaceutical developers worldwide, growers and researchers.

• Position itself uniquely as a first mover in the emerging field of frequency based plant optimization.

How We Estimate Haivya’s Valuation

Venture capital investors often use forward looking valuation models that estimate a company’s exit value, time horizon, expected return and ownership stake. Haivya’s projected valuation is rooted in this same framework.

Based on our current roadmap and market indicators:

• Projected Exit Value: $1 billion +

• Expected Exit Timeline: 4 years

• Target Return for Early Investors: 5x-10x

• Anticipated Investor Ownership at Exit: 10-15%

Importantly, this model does not yet account for the additional upside tied to our proprietary IP, novel phenotypic expression, or the expected validation from lab results. once third party analysis confirms what our morphology already suggests, we anticipate a significant abrupt increase in valuation, making this window a rare early stage entry point for aligned partners.

This is a Once-in-a-Generation Moment

We believe that intention and love changes everything and now, the data is beginning to show it.